CREO — Creo Medical Income Statement
0.000.00%
Last trade - 00:00
- £125.53m
- £108.23m
- £27.17m
- 44
- 16
- 62
- 32
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 18 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.013 | 9.43 | 25.2 | 27.2 |
Cost of Revenue | |||||
Gross Profit | 0 | 0.005 | 4.04 | 11.6 | 13.1 |
Selling / General / Administrative Expenses | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 17.7 | 18.9 | 32.9 | 55.1 | 57.9 |
Operating Profit | -17.7 | -18.9 | -23.5 | -29.9 | -30.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -17.6 | -18.6 | -23.5 | -30.3 | -31 |
Provision for Income Taxes | |||||
Net Income After Taxes | -14.8 | -15.9 | -20.3 | -24.6 | -26.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -14.8 | -15.9 | -20.3 | -24.6 | -26.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -14.8 | -15.9 | -20.3 | -24.6 | -26.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.158 | -0.126 | -0.125 | -0.144 | -0.143 |
Dividends per Share |